Nektar Therapeutics (NKTR) Short Interest Ratio & Short Volume $8.59 -0.17 (-1.94%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.66 +0.07 (+0.87%) As of 06/13/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Nektar Therapeutics Short Interest DataNektar Therapeutics (NKTR) has a short interest of 753,700 shares, representing 0.42% of the float (the number of shares available for trading by the public). This marks a -92.93% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.4, indicating that it would take 4.4 days of the average trading volume of 135,933 shares to cover all short positions.Current Short Interest753,700 sharesPrevious Short Interest10,660,000 sharesChange Vs. Previous Month-92.93%Dollar Volume Sold Short$8.18 millionShort Interest Ratio4.4 Days to CoverLast Record DateMay 31, 2025Outstanding Shares186,104,000 sharesShort Percent of Float0.42%Today's Trading Volume441,266 sharesAverage Trading Volume135,933 sharesToday's Volume Vs. Average325% Short Selling Nektar Therapeutics? Sign up to receive the latest short interest report for Nektar Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNKTR Short Interest Over TimeNKTR Days to Cover Over TimeNKTR Percentage of Float Shorted Over Time Nektar Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/2025753,700 shares $8.18 million -92.9%0.4%4.4 $10.85 5/15/202510,660,000 shares $7.25 million +19.4%5.9%5.2 $0.68 4/30/20258,930,000 shares $7.10 million +9.7%5.0%3.6 $0.80 4/15/20258,140,000 shares $5.19 million +4.8%4.5%3.4 $0.64 3/31/20257,770,000 shares $5.28 million +11.8%4.3%3.5 $0.68 3/15/20256,950,000 shares $6.23 million +5.0%3.9%3.5 $0.90 2/28/20256,620,000 shares $5.58 million -11.5%3.7%3.1 $0.84 2/15/20257,480,000 shares $7.35 million +29.9%4.2%3.4 $0.98 1/31/20255,760,000 shares $4.77 million +22.0%3.2%3 $0.83 1/15/20254,720,000 shares $4.27 million +8.5%2.7%2.6 $0.91 Get the Latest News and Ratings for NKTR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20244,350,000 shares $4.05 million -1.1%2.5%2.4 $0.93 12/15/20244,400,000 shares $4.44 million -0.9%2.5%2.5 $1.01 11/30/20244,440,000 shares $5.06 million -13.5%2.5%2.7 $1.14 11/15/20245,130,000 shares $5.49 million -1.9%2.9%3.7 $1.07 10/31/20245,230,000 shares $6.22 million -13.4%2.9%4.4 $1.19 10/15/20246,040,000 shares $7.79 million -17.4%3.4%5.9 $1.29 9/30/20247,310,000 shares $9.50 million -5.8%4.1%7.1 $1.30 9/15/20247,760,000 shares $10.17 million -5.8%4.4%5.2 $1.31 8/31/20248,240,000 shares $10.55 million -2.7%4.6%5.2 $1.28 8/15/20248,470,000 shares $10.08 million -4.1%4.8%4.9 $1.19 7/31/20248,830,000 shares $11.83 million -9.2%4.9%4.7 $1.34 7/15/20249,720,000 shares $13.61 million +140.0%5.4%5 $1.40 6/30/20244,050,000 shares $5.02 million -6.7%2.3%1.7 $1.24 6/15/20244,340,000 shares $5.08 million +58.4%2.4%1.9 $1.17 5/31/20242,740,000 shares $3.48 million +3.4%1.5%1.3 $1.27 5/15/20242,650,000 shares $4.85 million -25.1%1.5%1 $1.83 4/30/20243,540,000 shares $5.17 million +13.8%2.0%1.4 $1.46 4/15/20243,110,000 shares $4.88 million +31.8%1.8%1.3 $1.57 3/31/20242,360,000 shares $2.20 million -6.0%1.3%1.2 $0.93 3/15/20242,510,000 shares $2.16 million +24.9%1.4%1.6 $0.86 2/29/20242,010,000 shares $1.43 million -18.0%1.1%1.2 $0.71 2/15/20242,450,000 shares $1.81 million -57.8%N/A2 $0.74 1/31/20245,800,000 shares $3.15 million +6.6%N/A4.8 $0.54 1/15/20245,440,000 shares $2.91 million +1.7%N/A3.7 $0.53 12/31/20235,350,000 shares $3.02 million -23.1%N/A3.4 $0.57 12/15/20236,960,000 shares $3.26 million -3.7%N/A4.5 $0.47 11/30/20237,230,000 shares $3.54 million -9.7%N/A4.6 $0.49 11/15/20238,010,000 shares $4.21 million +7.2%N/A4.7 $0.53 10/31/20237,470,000 shares $3.50 million -8.8%N/A2.8 $0.47 10/15/20238,190,000 shares $4.41 million +5.8%N/A1.4 $0.54Trump’s Manhattan Project (Ad)The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washington… even Trump’s obsession with seizing Greenland. There’s a singular force that connects the dots… And it could threaten to transform American life – and your wealth – forever. You can get all the details here. 9/30/20237,740,000 shares $4.61 million +6.6%N/A1.3 $0.60 9/15/20237,260,000 shares $5.12 million +7.1%N/A1.2 $0.71 8/31/20236,780,000 shares $4.03 million -5.2%N/A1 $0.60 8/15/20237,150,000 shares $5.79 million +23.3%N/A1 $0.81 7/31/20235,800,000 shares $3.11 million +9.9%N/A0.9 $0.54 7/15/20235,280,000 shares $2.90 million -2.8%N/A1.5 $0.55 6/30/20235,430,000 shares $3.12 million -50.8%N/A1.4 $0.58 6/15/202311,030,000 shares $6.23 million +11.5%N/A2 $0.56 5/31/20239,890,000 shares $5.74 million -2.1%N/A2 $0.58 5/15/202310,100,000 shares $7.71 million +5.4%N/A2 $0.76 4/30/20239,580,000 shares $7.21 million +16.7%5.8%2 $0.75 4/15/20238,210,000 shares $7.60 million -3.5%N/A1.7 $0.93 3/31/20238,510,000 shares $5.98 million +20.2%N/A1.9 $0.70 3/15/20237,080,000 shares $8.07 million -19.1%N/A2.9 $1.14 2/28/20238,750,000 shares $12.08 million -11.8%N/A4.5 $1.38 2/15/20239,920,000 shares $30.85 million -0.1%N/A4.9 $3.11 1/31/20239,930,000 shares $27.01 million +7.7%N/A6.1 $2.72 1/15/20239,220,000 shares $23.23 million +2.4%N/A5.9 $2.52 12/30/20229,000,000 shares $20.34 million -1.6%N/A5.6 $2.26 12/15/20229,150,000 shares $24.71 million -44.4%N/A5.3 $2.70 11/30/202216,470,000 shares $46.12 million -1.9%N/A9 $2.80 11/15/202216,790,000 shares $65.82 million -3.2%N/A10.6 $3.92 10/31/202217,350,000 shares $65.24 million -0.2%N/A10.6 $3.76 10/15/202217,390,000 shares $61.73 million -0.6%N/A9.5 $3.55 9/30/202217,500,000 shares $56 million -0.5%N/A7.7 $3.20 9/15/202217,590,000 shares $64.38 million -0.2%N/A6.5 $3.66 8/31/202217,630,000 shares $69.46 million -6.5%N/A6.1 $3.94 8/15/202218,860,000 shares $92.60 million -0.7%N/A6.1 $4.91 7/31/202219,000,000 shares $75.24 million -19.4%N/A5.7 $3.96 7/15/202223,560,000 shares $84.34 million +17.1%N/A6.6 $3.58 6/30/202220,120,000 shares $76.46 million +14.1%N/A5.2 $3.80 6/15/202217,640,000 shares $59.27 million -1.2%N/A4.4 $3.36 5/31/202217,860,000 shares $62.15 million -1.3%N/A4.2 $3.48 5/15/202218,100,000 shares $72.22 million -1.3%N/A4.4 $3.99 4/30/202218,330,000 shares $75.70 million -10.3%N/A4.7 $4.13 4/15/202220,430,000 shares $125.85 million -2.3%N/A5.6 $6.16 3/31/202220,920,000 shares $112.76 million -12.1%N/A7 $5.39 3/15/202223,790,000 shares $106.58 million +11.5%N/A8.6 $4.48 2/28/202221,330,000 shares $218.42 million +3.6%N/A8.3 $10.24 2/15/202220,580,000 shares $230.08 million +4.7%11.4%8.2 $11.18 1/31/202219,660,000 shares $218.62 million +6.3%10.8%7.8 $11.12 1/15/202218,500,000 shares $223.85 million -2.5%10.2%7.6 $12.10 12/31/202118,980,000 shares $256.42 million +11.3%10.4%8.7 $13.51 12/15/202117,060,000 shares $221.10 million +5.7%9.4%8.4 $12.96 11/30/202116,140,000 shares $181.74 million -4.0%8.9%12.1 $11.26 11/15/202116,820,000 shares $224.38 million +3.2%9.2%14.9 $13.34 10/29/202116,300,000 shares $247.11 million +1.6%9.0%15.8 $15.16 10/15/202116,040,000 shares $277.65 million -0.9%8.8%18.7 $17.31 9/30/202116,190,000 shares $290.77 million -1.8%8.9%18.9 $17.96 9/15/202116,480,000 shares $266.65 million -5.0%9.1%19 $16.18[Wanted] 250 intrepid souls (Ad)He Called this 106X Opportunity Before Reddit… and Before Elon Musk Before GameStop rocketed up to 10,633, Jonathan Rose saw something strange: A sudden surge in options volume — thousands of contracts flooding in. The money hit deep inside the CBOE before Reddit posts created the short squeeze and before Elon's tweet sent GameStop flying. Jonathan calls it the "Big-Money Tell," and it's flagged dozens of big trade opportunities including: 462.5% in C3.ai, 245.13% in Criteo, and 39.46% in Roku. And these are just some of the gains the "tell" has identified. Even better: He says the next big set-up could be forming right now. And there's still time for you to get in before it kicks off as soon as seven days from now.Click here for the details from Jonathan himself. 8/31/202117,350,000 shares $268.58 million -1.5%9.6%20.4 $15.48 8/13/202117,620,000 shares $251.79 million -2.0%9.7%20.9 $14.29 7/30/202117,970,000 shares $283.75 million +0.7%10.0%21 $15.79 7/15/202117,840,000 shares $295.97 million -1.8%9.9%19.8 $16.59 6/30/202118,160,000 shares $311.63 million -0.8%10.1%20 $17.16 6/15/202118,310,000 shares $325.00 million +1.5%10.2%20.8 $17.75 5/28/202118,040,000 shares $325.98 million -0.4%10.0%20.7 $18.07 5/14/202118,110,000 shares $341.55 million -5.9%N/A19.9 $18.86 4/30/202119,240,000 shares $386.53 million -2.2%N/A18.2 $20.09 4/15/202119,680,000 shares $376.68 million +2.1%N/A16 $19.14 3/31/202119,280,000 shares $376.15 million -3.3%N/A15.3 $19.51 3/15/202119,940,000 shares $455.03 million -6.2%N/A14.9 $22.82 2/26/202121,250,000 shares $476.85 million +0.4%N/A15.9 $22.44 2/12/202121,160,000 shares $481.39 million -7.6%N/A16.7 $22.75 1/29/202122,900,000 shares $422.28 million -4.5%N/A19.4 $18.44 1/15/202123,970,000 shares $426.67 million -1.0%N/A22.6 $17.80 12/31/202024,200,000 shares $434.15 million -1.5%N/A24 $17.94 12/15/202024,560,000 shares $433.24 million -0.3%N/A23.8 $17.64 11/30/202024,640,000 shares $413.71 million -0.2%N/A23.7 $16.79 11/15/202024,700,000 shares $426.57 million -2.1%N/A22.9 $17.27 10/30/202025,240,000 shares $409.14 million -2.5%N/A23.8 $16.21 10/15/202025,890,000 shares $454.11 million +1.7%N/A26.4 $17.54 9/30/202025,470,000 shares $422.55 million -1.3%N/A27.5 $16.59 9/15/202025,800,000 shares $516.26 million -1.7%N/A28.3 $20.01 8/31/202026,240,000 shares $507.48 million -0.7%N/A29 $19.34 8/14/202026,420,000 shares $516.51 million -1.3%N/A27.5 $19.55 7/31/202026,770,000 shares $593.22 million +0.1%N/A26 $22.16 7/15/202026,740,000 shares $630.80 million -2.3%N/A24.5 $23.59 6/30/202027,360,000 shares $613.41 million -1.2%N/A23 $22.42 6/15/202027,700,000 shares $567.57 million +3.3%N/A22.3 $20.49 NKTR Short Interest - Frequently Asked Questions What is Nektar Therapeutics' current short interest? Short interest is the volume of Nektar Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, traders have sold 753,700 shares of NKTR short. 0.42% of Nektar Therapeutics' shares are currently sold short. Learn More on Nektar Therapeutics' current short interest. What is a good short interest ratio for Nektar Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NKTR shares currently have a short interest ratio of 4.0. Learn More on Nektar Therapeutics's short interest ratio. Which institutional investors are shorting Nektar Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Nektar Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Nektar Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.42% of Nektar Therapeutics' floating shares are currently sold short. Is Nektar Therapeutics' short interest increasing or decreasing? Nektar Therapeutics saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 753,700 shares, a drop of 92.9% from the previous total of 10,660,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Nektar Therapeutics' short interest compare to its competitors? 0.42% of Nektar Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Nektar Therapeutics: Perrigo Company plc (3.86%), Supernus Pharmaceuticals, Inc. (7.98%), Pacira BioSciences, Inc. (13.49%), Omeros Co. (21.86%), Assembly Biosciences, Inc. (0.35%), Cumberland Pharmaceuticals Inc. (0.75%), Eli Lilly and Company (0.95%), Johnson & Johnson (0.80%), AbbVie Inc. (0.90%), Merck & Co., Inc. (1.38%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Nektar Therapeutics stock? Short selling NKTR is an investing strategy that aims to generate trading profit from Nektar Therapeutics as its price is falling. NKTR shares are trading down $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nektar Therapeutics? A short squeeze for Nektar Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NKTR, which in turn drives the price of the stock up even further. How often is Nektar Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NKTR, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies PRGO Short Interest SUPN Short Interest PCRX Short Interest OMER Short Interest ASMB Short Interest CPIX Short Interest LLY Short Interest JNJ Short Interest ABBV Short Interest MRK Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NKTR) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
